论文部分内容阅读
目的:研究Galectin-3在肾细胞癌中的表达,探讨它与肾细胞癌的临床病理意义。方法:用免疫组化SP法检测Galectin-3在83例肾细胞癌和18例正常肾组织中的表达,结合临床病理数据,分析其与肾细胞癌临床病理特征之间的关系。结果:Galectin-3在透明细胞癌中的阳性表达率为38.89%(21/54),在乳头状细胞癌中的阳性表达率为68.42%(13/19),在嫌色细胞癌中的阳性表达率为80.00%(8/10),正常肾组织中阳性表达率为11.11%(2/18)。差异有统计学意义。Galectin-3在肾细胞癌中的表达与肾细胞癌病理学分级、临床分期、淋巴结转移及病理类型有关(P<0.05);而与患者性别、年龄和肿瘤直径无关(P>0.05)。结论:Galectin-3的高表达与肾细胞癌,特别是乳头状细胞癌和嫌色细胞癌的发生、发展密切相关,为肾细胞癌的鉴别诊断及临床治疗提供了可参考的指标。
OBJECTIVE: To study the expression of Galectin-3 in renal cell carcinoma and to explore the clinicopathological significance of Galectin-3 in renal cell carcinoma. Methods: The expression of Galectin-3 in 83 cases of renal cell carcinoma and 18 cases of normal renal tissues was detected by immunohistochemical SP method. The relationship between Galectin-3 and clinical and pathological features of renal cell carcinoma was analyzed by clinicopathological data. Results: The positive expression rate of Galectin-3 in clear cell carcinoma was 38.89% (21/54), and the positive expression rate in papillary carcinoma was 68.42% (13/19). The positive expression rate of Galectin-3 in chromophobe The positive rate was 80.00% (8/10) in normal renal tissues and 11.11% (2/18) in normal renal tissues. The difference was statistically significant. The expression of Galectin-3 in renal cell carcinoma was related to pathological grade, clinical stage, lymph node metastasis and pathological type of renal cell carcinoma (P <0.05), but not to gender, age and tumor diameter (P> 0.05). Conclusion: The high expression of Galectin-3 is closely related to the occurrence and development of renal cell carcinoma, especially papillary carcinoma and chromophobe carcinoma, and provides a reference index for the differential diagnosis and clinical treatment of renal cell carcinoma.